BRPI0822556B1 - Anticorpo monoclonal anti-vegf e composição farmacêutica - Google Patents

Anticorpo monoclonal anti-vegf e composição farmacêutica Download PDF

Info

Publication number
BRPI0822556B1
BRPI0822556B1 BRPI0822556-7A BRPI0822556A BRPI0822556B1 BR PI0822556 B1 BRPI0822556 B1 BR PI0822556B1 BR PI0822556 A BRPI0822556 A BR PI0822556A BR PI0822556 B1 BRPI0822556 B1 BR PI0822556B1
Authority
BR
Brazil
Prior art keywords
antibody
amino acid
antibodies
acid sequence
variable domain
Prior art date
Application number
BRPI0822556-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Yaohuang Ke
Weimin Zhu
Guo-Liang Yu
Original Assignee
Epitomics, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitomics, Inc filed Critical Epitomics, Inc
Publication of BRPI0822556A2 publication Critical patent/BRPI0822556A2/pt
Publication of BRPI0822556B1 publication Critical patent/BRPI0822556B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0822556-7A 2008-03-26 2008-10-08 Anticorpo monoclonal anti-vegf e composição farmacêutica BRPI0822556B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3971908P 2008-03-26 2008-03-26
US61/039,719 2008-03-26
PCT/US2008/011620 WO2009120178A1 (en) 2008-03-26 2008-10-08 Anti-vegf antibody

Publications (2)

Publication Number Publication Date
BRPI0822556A2 BRPI0822556A2 (pt) 2020-08-18
BRPI0822556B1 true BRPI0822556B1 (pt) 2022-03-03

Family

ID=41114205

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822556-7A BRPI0822556B1 (pt) 2008-03-26 2008-10-08 Anticorpo monoclonal anti-vegf e composição farmacêutica

Country Status (9)

Country Link
US (2) US7803371B2 (enExample)
EP (1) EP2259795B1 (enExample)
JP (2) JP5823858B2 (enExample)
KR (1) KR101581244B1 (enExample)
CN (2) CN102065888B (enExample)
AU (1) AU2008353479B2 (enExample)
BR (1) BRPI0822556B1 (enExample)
CA (3) CA2981887C (enExample)
WO (1) WO2009120178A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180005753A (ko) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
JP2013508308A (ja) * 2009-10-23 2013-03-07 ガーバン インスティテュート オブ メディカル リサーチ 修飾可変ドメイン分子、ならびにその産生および使用方法
CN103502274B (zh) 2011-03-03 2016-01-06 埃派斯进有限公司 抗-il-6受体抗体及其使用方法
CN104650229A (zh) * 2011-11-02 2015-05-27 埃派斯进有限公司 抗-kdr抗体和使用方法
CN103417964A (zh) * 2012-05-17 2013-12-04 江苏先声药物研究有限公司 一种抗vegf抗体的用途
CN103417965B (zh) * 2012-05-17 2018-04-13 江苏先声药业有限公司 一种含有抗vegf抗体的药物组合物
MY170528A (en) 2013-02-18 2019-08-09 Vegenics Pty Ltd Vegfr-3 ligand binding molecules and uses thereof
JP2016530244A (ja) * 2013-12-31 2016-09-29 ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 抗ｖｅｇｆ抗体及びその使用
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
MX2017009253A (es) * 2015-01-16 2017-10-12 Alder Biopharmaceuticals Inc Anticuerpos antiglicoproteina y usos de los mismos.
CA2991264C (en) * 2015-07-06 2023-10-10 Ucb Biopharma Sprl Tau-binding antibodies
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
MX2022002855A (es) * 2019-09-13 2022-06-02 Admare Therapeutics Soc Anticuerpos antiantígenos de virus oncolíticos y métodos de uso de los mismos.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2024145219A2 (en) * 2022-12-29 2024-07-04 Ltz Therapeutics Inc. Anti-cd79b antibodies and uses thereof
CN118344476B (zh) * 2024-05-16 2024-11-15 武汉爱博泰克生物科技有限公司 人c反应蛋白单克隆抗体、抗体对和检测试剂或试剂盒及其应用
CN120971725B (zh) * 2025-07-24 2026-06-30 浙江隆基生物技术有限公司 一种分泌靶标物质的阳性单个b细胞的筛选方法及单克隆抗体制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
CN1299833A (zh) * 1999-12-30 2001-06-20 华西医科大学口腔医学研究所 抗人血管内皮生长因子单链抗体及其制备方法
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
AU2003264009A1 (en) * 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
CN100415765C (zh) * 2003-08-07 2008-09-03 宜康公司 兔单克隆抗体的人源化方法
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
PL2307458T3 (pl) * 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物

Also Published As

Publication number Publication date
US20090246190A1 (en) 2009-10-01
US7803371B2 (en) 2010-09-28
JP2011517447A (ja) 2011-06-09
CN102065888A (zh) 2011-05-18
HK1201280A1 (en) 2015-08-28
US8088375B2 (en) 2012-01-03
CA2719400C (en) 2017-11-14
CN102065888B (zh) 2014-03-26
WO2009120178A1 (en) 2009-10-01
CA2981887C (en) 2019-09-03
CA3053675A1 (en) 2009-10-01
AU2008353479B2 (en) 2014-02-20
US20110008367A1 (en) 2011-01-13
JP2014205674A (ja) 2014-10-30
KR20100132983A (ko) 2010-12-20
CN103992405A (zh) 2014-08-20
EP2259795A1 (en) 2010-12-15
EP2259795A4 (en) 2012-06-06
CN103992405B (zh) 2016-08-17
KR101581244B1 (ko) 2015-12-31
EP2259795B1 (en) 2016-04-06
JP5823858B2 (ja) 2015-11-25
BRPI0822556A2 (pt) 2020-08-18
CA2981887A1 (en) 2009-10-01
CA2719400A1 (en) 2009-10-01
AU2008353479A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
CN102065888B (zh) 抗-vegf抗体
JP6823094B2 (ja) Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
JP5513888B2 (ja) グルカゴン受容体抗体に関する組成物および方法
JP5738294B2 (ja) 抗ｖｅｇｆモノクローナル抗体およびその抗体を含む薬学的組成物
BR112021010402A2 (pt) Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos
WO2005087812A1 (en) Multivalent antibody materials and methods for vegf/pdgf family of growth factors
CN104861068A (zh) 一种全人源抗her3抗体及含有该抗体的组合物和其用于制备治疗her3相关疾病的药物中的用途
CN118271438A (zh) 抗cgrp抗体或其抗原结合片段及其用途
AU2014202474B2 (en) Anti-VEGF antibody
CN115956089A (zh) 抑制性抗enpp1抗体
JP7564882B2 (ja) Ａｒｅｇに対する抗体及びその用途
HK1201280B (en) Anti-vegf antibody
WO2026044246A1 (en) Anti-cadherin-17 antibodies and use thereof
EP2662386B1 (en) Antibodies that bind to PLAC1 and block interaction between PLAC1 and FGF7
CN117244055A (zh) Cd70抗体的药物组合物及其应用
HK40005045B (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
BR122026002676A2 (pt) Anticorpo e seus usos, polinucleotídeo isolado, vetor, composição farmacêutica, método de produzir o anticorpo ou fragmento do mesmo
BR122021001159B1 (pt) Anticorpo do receptor acoplado à anti-proteína g família c grupo 5 membro d (gprc5d) ou fragmento de ligação ao antígeno do mesmo, seu uso, composições, imunoconjugado, molécula biespecífica, molécula de ácido nucleico, vetor de expressão, método para detecção de gprc5d em uma célula inteira ou tecido e kit para tratar um tumor

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/10/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.